Hyaluronic acid/triamcinolone acetonide - Carbylan Therapeutics

Drug Profile

Hyaluronic acid/triamcinolone acetonide - Carbylan Therapeutics

Alternative Names: Hydros-TA

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Carbylan BioSurgery
  • Developer KalVista Pharmaceuticals
  • Class Analgesics; Corticosteroids; Fluorinated steroids; Glycosaminoglycans; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Pain

Most Recent Events

  • 22 Nov 2016 Carbylan Therapeutics has been acquired and merged into KalVista Pharmaceuticals
  • 01 Jun 2016 Carbylan completes a phase III clinical trial for Pain in Netherlands Antilles, Australia, Canada, Europe, New Zealand (Intra-articular) (9190751; NCT02022930)
  • 22 Apr 2016 Suspended - Phase-II for Pain in West Indies (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top